Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? the Losartan Intervention for Endpoint reduction in hypertension study
Diabetes Mellitus, Type 2
Hypertrophy, Left Ventricular
During follow-up of hypertensive patients with LVH, occurrence of MI but not coronary revascularization as first cardiovascular event significantly increased risk of subsequent cardiovascular death, all-cause death, and stroke. In view of differences in prognostic implications, when the goal is to have a prognostically relevant composite endpoint for trials in hypertensive patients, caution should be used in combining coronary revascularization with MI.